-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] This week (January 24-January 30), there were 5 new A-share subscriptions, including Sanyuan Bio, AsiaInfo Security, Dongwei Semiconductor, Guangdong Group, and Kunheng Shunwei
.
In the next week, there will be 3 new shares for subscription, including 1 new pharmaceutical stock, Hualan Vaccine.
The proposed acquisition date of the new pharmaceutical stock is set for February 8, 2022
.
Recently, the prospectus disclosed by Hualan Vaccine shows that the company plans to issue 40.
01 million shares for the first time, accounting for 10% of the total share capital after the issuance, and the total share capital after the issuance is 400.
01 million shares
.
Among them, the number of subscriptions for the special asset management plan established by the company's senior management and core employees participating in this strategic placement shall not exceed 10% of the number of this issuance, that is, no more than 4,001,000 shares, and the subscription amount shall not exceed 252 million yuan; The number of follow-up investments by related subsidiaries is expected to be no more than 5% of the number of this offering
.
In addition, the initial strategic placement of this issue is 6,001,500 shares, accounting for 15.
00% of the issued number
.
Before the start of the callback mechanism, the initial offline issuance amount was 27.
207 million shares, accounting for 80.
00% of the total issuance after deducting the initial strategic placement; the online initial issuance amount was 6.
8015 million shares, accounting for the total issuance after deducting the initial strategic placement.
20.
00% of the amount
.
Hualan Vaccine is a subsidiary of Hualan Bio, and its main business is the research and development, production and sales of human vaccines
.
During the reporting period, the company's main business products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A (H1N1) split vaccine,
etc.
In terms of research pipelines, there are currently 11 Hualan vaccines under development, of which 3 have been declared for production, 1 is in Phase III and 1 is in Phase 2 clinical trials
.
For the funds raised this time, the company plans to invest in the following projects: 1.
084 billion yuan for influenza vaccine development and industrialization and existing product supply guarantee capacity building projects, 86 million yuan for freeze-dried human rabies vaccine development and industrialization Construction projects, 274 million yuan for the development and industrialization of multi-bacterial vaccines, 761 million yuan for the development and industrialization of new pneumonia vaccines, and 290 million yuan for the construction of new vaccine research and development platforms, totaling 2.
495 billion yuan Yuan
.
Financial data shows that the company's net profit has gradually increased in recent years
.
In 2018, 2019 and 2020, net profits attributable to owners of the parent company after deducting non-recurring gains and losses were 212 million yuan, 358 million yuan and 899 million yuan respectively
.
According to the company's 2021 performance forecast released on January 24, operating income in 2021 is expected to be 1.
941 billion to 2.
669 billion yuan, a year-on-year decrease of 10% to 20%
.
Net profit attributable to owners of the parent company was 740 million to 1.
017 billion yuan, down 10% to 20% year-on-year
.
Net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 710 million to 980 million yuan, down 9% to 21% year-on-year
.
Regarding the reasons for this change in performance, the company stated that the sales of its main product, quadrivalent influenza virus split vaccine, have very obvious seasonal characteristics and are mainly concentrated in the second half of each year
.
Affected by the epidemic in some parts of China in the fourth quarter of 2021, and the start of vaccine booster shots and vaccinations for children under 12 years old, the company's influenza vaccination was affected, resulting in a decline in performance
.
It is understood that Hualan Vaccine, as a domestic quadrivalent influenza vaccine giant, has always received high market attention
.
Because its parent company, Hualan Bio, is a domestic giant in the blood products industry, and Hualan Vaccine is the "only child" engaged in vaccine development and production in the Hualan Biosystem, the progress of Hualan Vaccine's listing has attracted more attention from many investors
.
.
In the next week, there will be 3 new shares for subscription, including 1 new pharmaceutical stock, Hualan Vaccine.
The proposed acquisition date of the new pharmaceutical stock is set for February 8, 2022
.
Recently, the prospectus disclosed by Hualan Vaccine shows that the company plans to issue 40.
01 million shares for the first time, accounting for 10% of the total share capital after the issuance, and the total share capital after the issuance is 400.
01 million shares
.
Among them, the number of subscriptions for the special asset management plan established by the company's senior management and core employees participating in this strategic placement shall not exceed 10% of the number of this issuance, that is, no more than 4,001,000 shares, and the subscription amount shall not exceed 252 million yuan; The number of follow-up investments by related subsidiaries is expected to be no more than 5% of the number of this offering
.
In addition, the initial strategic placement of this issue is 6,001,500 shares, accounting for 15.
00% of the issued number
.
Before the start of the callback mechanism, the initial offline issuance amount was 27.
207 million shares, accounting for 80.
00% of the total issuance after deducting the initial strategic placement; the online initial issuance amount was 6.
8015 million shares, accounting for the total issuance after deducting the initial strategic placement.
20.
00% of the amount
.
Hualan Vaccine is a subsidiary of Hualan Bio, and its main business is the research and development, production and sales of human vaccines
.
During the reporting period, the company's main business products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A (H1N1) split vaccine,
etc.
In terms of research pipelines, there are currently 11 Hualan vaccines under development, of which 3 have been declared for production, 1 is in Phase III and 1 is in Phase 2 clinical trials
.
For the funds raised this time, the company plans to invest in the following projects: 1.
084 billion yuan for influenza vaccine development and industrialization and existing product supply guarantee capacity building projects, 86 million yuan for freeze-dried human rabies vaccine development and industrialization Construction projects, 274 million yuan for the development and industrialization of multi-bacterial vaccines, 761 million yuan for the development and industrialization of new pneumonia vaccines, and 290 million yuan for the construction of new vaccine research and development platforms, totaling 2.
495 billion yuan Yuan
.
Financial data shows that the company's net profit has gradually increased in recent years
.
In 2018, 2019 and 2020, net profits attributable to owners of the parent company after deducting non-recurring gains and losses were 212 million yuan, 358 million yuan and 899 million yuan respectively
.
According to the company's 2021 performance forecast released on January 24, operating income in 2021 is expected to be 1.
941 billion to 2.
669 billion yuan, a year-on-year decrease of 10% to 20%
.
Net profit attributable to owners of the parent company was 740 million to 1.
017 billion yuan, down 10% to 20% year-on-year
.
Net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 710 million to 980 million yuan, down 9% to 21% year-on-year
.
Regarding the reasons for this change in performance, the company stated that the sales of its main product, quadrivalent influenza virus split vaccine, have very obvious seasonal characteristics and are mainly concentrated in the second half of each year
.
Affected by the epidemic in some parts of China in the fourth quarter of 2021, and the start of vaccine booster shots and vaccinations for children under 12 years old, the company's influenza vaccination was affected, resulting in a decline in performance
.
It is understood that Hualan Vaccine, as a domestic quadrivalent influenza vaccine giant, has always received high market attention
.
Because its parent company, Hualan Bio, is a domestic giant in the blood products industry, and Hualan Vaccine is the "only child" engaged in vaccine development and production in the Hualan Biosystem, the progress of Hualan Vaccine's listing has attracted more attention from many investors
.
